Zevra Therapeutics, Inc. (ZVRA) News
Track canonical SquawkNews coverage tagged to ZVRA, Zevra Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Zevra Therapeutics to Present at Conference
Zevra Therapeutics presents at growth conference
EQUITY | Aug 04, 2026, 11:30 AM UTC
M
Zevra Therapeutics Publishes Real-World Data
Zevra publishes 4-year data on MIPLYFFA in NPC
EQUITY | Aug 03, 2026, 11:30 AM UTC
L
ZVRA Reiterate Buy, though lower PT to $20 (from $29) after unfortunate European outcome @ Canaccord
ZVRA Reiterate Buy, though lower PT to $20 (from $29) after unfortunate European outcome @ Canaccord
EQUITY | Jul 27, 2026, 12:55 PM UTC
L
ZVRA -31% premarket after EMA panel issues negative opinion on Zevra arimoclomol EU marketing application for Niemann-Pick disease type C
ZVRA -31% premarket after EMA panel issues negative opinion on Zevra arimoclomol EU marketing application for Niemann-Pick disease type C
EQUITY | Jul 24, 2026, 12:08 PM UTC
M
ZVRA: Publishes Positive MIPLYFFA Data
Zevra Therapeutics announces publication of positive MIPLYFFA data from pediatric substudy in infants with Niemann-Pick Disease Type C
EQUITY | Jun 23, 2026, 11:31 AM UTC